A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer

Affiliation auteurs!!!! Error affiliation !!!!
TitreA randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer
Type de publicationJournal Article
Year of Publication2017
AuteursPivot XB, Bondarenko I, Dvorkin M, Trishkina E, Ahn J-H, Im S-A, Sarosiek T, Chattopadhyay S, Wojtukiewicz M, Moiseyenko V, Shparyk YV, Bello MDe Guzman, Semiglazov V, Song S, Lim JYun
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.15_suppl.509